Circulating tumor DNA guided extra treatment for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage II or III breast cancer, but not occult, inflammatory, or metaplastic types.
- You must have triple-negative breast cancer, which means your tumor has low or no estrogen and progesterone receptors, and HER2 is negative.
- You must have had neoadjuvant (before surgery) therapy and still have some cancer remaining after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.